Subconjunctival autologous platelet-rich plasma as an adjunctive therapy for limbal–scleral ischemia following acute ocular burns: a prospective randomized pilot trial

Q: What does this research mean for the field?

Subconjunctival autologous platelet-rich plasma (PRP) injection is safe and feasible as an adjunct to topical PRP for acute ocular burns, but does not significantly improve limbal-scleral ischemic area healing compared to topical PRP alone. Novelty: ClaimNovelty.INCREMENTAL. Consensus alignment: ConsensusAlignment.NEUTRAL.

Mehrnaz Atighehchian; Hamed Ghassemi; Siamak Zarei-Ghanavati; Golshan Latifi; Mehran Zarei-Ghanavati

doi:10.1186/s12886-026-05225-6

August 17, 2026BMC OphthalmologyOpen Access

Subconjunctival autologous platelet-rich plasma as an adjunctive therapy for limbal–scleral ischemia following acute ocular burns: a prospective randomized pilot trial

View Full Paper

Ask AI

Bookmark

Share

Key Points

To evaluate the feasibility, safety, and short-term efficacy of subconjunctival autologous platelet-rich plasma injections as an adjunct to topical therapy for limbal–scleral ischemia following acute ocular burns.
Prospective randomized pilot trial including 16 eyes of 16 male patients (mean age 35.37 ± 11.42 years) presenting with limbal–scleral ischemic area (LSIA) within 3 weeks of chemical or thermal burns.
Participants were randomized via permuted blocks to receive standard medical therapy with topical platelet-rich plasma (PRP) eye drops alone or combined with a single subconjunctival autologous PRP injection.
Primary endpoint was best-corrected visual acuity (BCVA) at 3 months; secondary endpoints were change in LSIA size quantified with ImageJ and time to complete revascularization.
Mean BCVA improved from 1.44 ± 0.70 to 1.07 ± 0.95 logMAR across the cohort with no statistically significant difference between arms (p > 0.05).
Both groups achieved complete revascularization by month 3, with a mean healing time of 50 days (95% CI: 17.9–82.1) in Group 1 versus 44.75 days (95% CI: 20.0–69.5) in Group 2.
No injection-related adverse events occurred, confirming procedural safety despite no demonstrated superiority in revascularization rates.

No abstract yet

We only have this paper's title and publication details.

Read it at the source

Ask about this paper

Answers are grounded in this paper and cite their sources.

Implication

Randomized trial reveals subconjunctival platelet-rich plasma does not significantly accelerate revascularization in acute ocular burns, indicating standard topical therapy remains sufficient.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Atighehchian et al. (2026) studied this question.

synapsesocial.com/papers/6a8563ae03308d306e2d6f36 https://doi.org/10.1186/s12886-026-05225-6

View Full Paper

Ask AI

Bookmark

Share

Subconjunctival autologous platelet-rich plasma as an adjunctive therapy for limbal–scleral ischemia following acute ocular burns: a prospective randomized pilot trial

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Subconjunctival autologous platelet-rich plasma as an adjunctive therapy for limbal–scleral ischemia following acute ocular burns: a prospective randomized pilot trial

Key Points

No abstract yet

Ask about this paper

Implication

Discussion

Cite This Study

Keep reading

Keep reading